ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study.

Abstract

ICRF-159 is active in several animal tumor model systems and human adult malignancies. In this phase II study, ICRF-159 was given on a weekly schedule, 3000 mg/m2/day, orally in three divided doses at 6-hour intervals to 78 children with a variety of malignant neoplasms. Fifty-three patients were evaluable for tumor response. Toxicity was primarily hematopoietic and gastrointestinal. There were no responses in any of the eight patients with osteogenic sarcoma, four with lymphoma, five with Ewing's sarcoma, ten with neuroblastoma, or six with rhabdomyosarcoma. There was a transient partial response in one of four children with Wilms' tumor. Further trials with this drug using this schedule are not indicated for the common childhood solid tumors.

• Authors: P G Dyment, K A Starling, V J Land, A Cangir, D M Komp, C L Sexauer
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 63 Issue 8 Pg. 1397-8 (Aug 1979) ISSN: 0361-5960 [Print] United States
• PMID: 476712 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Piperazines
• Razoxane

Topics

• Adolescent
• Child
• Drug Administration Schedule
• Drug Evaluation
• Hematopoiesis (drug effects)
• Humans
• Neoplasms (drug therapy)
• Piperazines (therapeutic use)
• Razoxane (administration & dosage, adverse effects, therapeutic use)